Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKDB-501B in Glabellar Lines
NCT05428930Phase 1Completed
- Sponsor
- CKD BiO
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKDB-501B in glabellar lines (2 arms), sponsored by CKD BiO. Primary endpoint: Incidence of Adverse Events. Started Jun 2022; status: completed.
02
Drugs
CKDB-501B
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05428930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428930.